Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

HIV/AIDS 2010

HIV/AIDS 2010 EDITORIAL Better Drugs, Better Technologies, and Lingering Problems ROGRESS IN THE TREATMENT OF HUMAN IM- THE PROBLEM OF ADVERSE EFFECTS munodeficiency virus (HIV) and AIDS has been breathtaking. In the early 1980s, a di- Although highly effective, these drugs can cause serious agnosis of AIDS was thought to be synony- adverse effects. An observational analysis of the Swiss HIV P mous with death. Today, with available an- Cohort Study in this issue of the Archives found a high tiretroviral therapies, the life expectancy of HIV-infected rate of adverse effects that were serious enough to result persons nears that of age-matched uninfected persons. in a change or discontinuation of antiretroviral treat- ment: 22.4 modifications per 100 person-years. A strength A HISTORY OF HIV DRUG DEVELOPMENT of the study is that it evaluates the frequency of adverse IN 2 PARAGRAPHS effects much as a clinician would: is the adverse effect serious enough to require a change in treatment? In- This extraordinary progress in treatment is attributable deed, clinicians will find the data on treatment modifi- not to 1 drug or 1 study but to cumulative improve- cation resulting from toxic effects by regimen very help- ments over a 15-year period. The http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Loading next page...
 
/lp/american-medical-association/hiv-aids-2010-9yFsXSJQ0B
Publisher
American Medical Association
Copyright
Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2009.442
pmid
20065192
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL Better Drugs, Better Technologies, and Lingering Problems ROGRESS IN THE TREATMENT OF HUMAN IM- THE PROBLEM OF ADVERSE EFFECTS munodeficiency virus (HIV) and AIDS has been breathtaking. In the early 1980s, a di- Although highly effective, these drugs can cause serious agnosis of AIDS was thought to be synony- adverse effects. An observational analysis of the Swiss HIV P mous with death. Today, with available an- Cohort Study in this issue of the Archives found a high tiretroviral therapies, the life expectancy of HIV-infected rate of adverse effects that were serious enough to result persons nears that of age-matched uninfected persons. in a change or discontinuation of antiretroviral treat- ment: 22.4 modifications per 100 person-years. A strength A HISTORY OF HIV DRUG DEVELOPMENT of the study is that it evaluates the frequency of adverse IN 2 PARAGRAPHS effects much as a clinician would: is the adverse effect serious enough to require a change in treatment? In- This extraordinary progress in treatment is attributable deed, clinicians will find the data on treatment modifi- not to 1 drug or 1 study but to cumulative improve- cation resulting from toxic effects by regimen very help- ments over a 15-year period. The

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Jan 11, 2010

References